AVBP · ArriVent BioPharma, Inc.

$30.95 -0.08 (-0.26%) At close · Sep 4

Russell 2000 member Rebalance outlook locked

Market Cap

$1.53B

49.31M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Stuart Lutzker	M.D., Ph.D President, Research and Development	$515,779	—	—	$2,654,364	$247,574	$14,000	$3,431,717
Winston Kung	Chief Financial Officer and Treasurer	$492,417	—	—	$2,654,364	$246,287	$14,000	$3,407,068

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Winston Kung	MBA .................... Chief Financial Officer and Treasurer	$469,602	—	—	$1,190,331	$158,840	$13,800	$1,832,573
Stuart Lutzker	M.D., Ph.D.............. President, Research and Development	$495,941	—	—	$297,457	$179,035	$13,534	$985,967

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Stuart Lutzker	M.D., Ph.D.............. President, Research and Development	$476,867	—	—	$119,326	$219,359	$13,200	$828,752
Winston Kung	MBA .................... Chief Financial Officer and Treasurer	—	—	—	—	—	—	—

Key facts CIK 1868279 CUSIP 04272N102 13F (30d) 133 filings 133 filers Visit website Investor relations